Bio-Path Holdings, Inc. is advancing BP1001, a liposomal Grb2 antisense oligonucleotide, in a Phase 2a clinical trial targeting acute myeloid leukemia (AML) patients who are ineligible for intensive induction therapy. The combination of BP1001 with venetoclax and decitabine aims to enhance efficacy compared to historical controls. The AML market is characterized by a high unmet need, particularly for patients unable to tolerate aggressive chemotherapy. If successful, BP1001 could position Bio-Path favorably against established therapies, potentially capturing a significant share of the AML treatment landscape. The trial's design includes multiple cohorts, allowing for flexibility in patient selection and treatment optimization, which may enhance the asset's attractiveness to potential partners or acquirers.